MemoryGel Breast Implants: Final Safety and Efficacy Results after 10 Years of Follow-Up

• Published in: Plastic and reconstructive surgery (1963) Vol. 147; no. 3; p. 556
• Main Authors: Caplin, David A, Calobrace, M Bradley, Wixtrom, Roger N, Estes, Megan M, Canady, John W
• Format: Journal Article
• Language: English
• Published: United States 01.03.2021
• Subjects: Adolescent; Adult; Aged; Breast Implantation - instrumentation; Breast Implantation - methods; Breast Implants - adverse effects; Device Removal - statistics & numerical data; Female; Follow-Up Studies; Humans; Incidence; Kaplan-Meier Estimate; Middle Aged; Outcome Assessment, Health Care; Patient Safety - statistics & numerical data; Postoperative Complications - epidemiology; Postoperative Complications - etiology; Postoperative Complications - therapy; Prospective Studies; Prosthesis Failure; Reoperation - statistics & numerical data; United States; Young Adult; United States
• DOI: 10.1097/PRS.0000000000007635

Mentor MemoryGel Breast Implants were approved by the U.S. Food and Drug Administration in November of 2006. Patients in the Core clinical study supporting this approval were followed for 10 years. This prospective, multicenter, clinical study included primary augmentation, revision augmentation, primary reconstruction, and revision reconstruction patients implanted with smooth or Siltex Texture MemoryGel Implants. Incidence, severity, and method of resolution for all postoperative complications were assessed on per-patient and per-implant bases. The primary effectiveness endpoints were overall mean change in chest circumference and bra cup size following the implantation procedure. Primary augmentation (n = 552), revision augmentation (n = 145), primary reconstruction (n = 251), and revision reconstruction (n = 60) patients were enrolled in the study. Kaplan-Meier estimated 10-year cumulative incidence rates for key complications at the subject level for Baker grade III/IV capsular contracture were as follows: primary augmentation, 12.1 percent; revision augmentation, 24.4 percent; primary reconstruction, 20.5 percent; and revision reconstruction, 36.9 percent. For infection, rates were as follows: primary augmentation, 1.6 percent; revision augmentation, 1.4 percent; primary reconstruction, 6.2 percent; and revision reconstruction, 0 percent. For explantation with or without replacement, rates were as follows: primary augmentation, 11.6 percent; revision augmentation, 24.1 percent; primary reconstruction, 33.4 percent; and revision reconstruction; 37.8 percent. For rupture, rates were as follows: primary augmentation, 24.2 percent; revision augmentation, 23.7 percent; primary reconstruction, 32.7 percent; and revision reconstruction, 38.7 percent. For any reoperation, rates were as follows: primary augmentation, 25.5 percent; revision augmentation, 43.6 percent; primary reconstruction, 49.0 percent; and revision reconstruction, 50.7 percent. The results of this study demonstrate that MemoryGel Implants are safe and effective for use in women undergoing breast augmentation or reconstruction. Therapeutic, IV.